Results 11 to 20 of about 26,699 (253)

A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions

The Journal of Clinical Investigation
The myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility.
Julius Bogomolovas, Ju Chen
doaj   +2 more sources

Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]

Zhongguo quanke yixue
Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj   +2 more sources

Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review. [PDF]

Am J Cardiovasc Drugs
Hypertrophic cardiomyopathy (HCM) affects as many as 1 in 200 people in the adult population globally. Patients may present with exertional dyspnea, presyncope or syncope, atrial and ventricular arrhythmias, heart failure, and even sudden cardiac death.
Kalinski JK, Xu B, Boyd R, Tasseff N, Rutkowski K, Ospina S, Smedira N, Thamilarasan M, Popovic ZB, Desai MY.   +9 more
europepmc   +3 more sources

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying ...
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +4 more sources

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy

The Egyptian Heart Journal
Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of ...
Ikponmwosa Jude Ogieuhi, Victor Oluwatomiwa Ajekiigbe, Boluwaduro Abasiekem Adeyemi, Bright Nwatamole, Komolafe Babajide Ayodeji, Oshomoh Mark-Anthony Ugiomoh, Temiloluwa Adebayo Odeniyi, Adewunmi Akingbola, Efosa Peace Iyawe, Olabode Olawale Oladejo, Motunrayo Oluwatoyosi Lawal, Nathnael Abera Woldehana, Ifeoluwa Sandra Bakare, Adejumo Temilade Patience, Grace Chinenye Okoro   +14 more
doaj   +3 more sources

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants [PDF]

JACC Basic To Translational Science, 2022
Fady I Malik, Donghong Xu, Scott D Solomon   +2 more
exaly   +2 more sources

MMI‐0100 Inhibits Cardiac Fibrosis in a Mouse Model Overexpressing Cardiac Myosin Binding Protein C

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundCardiac stress can trigger production of a 40‐kDa peptide fragment derived from the amino terminus of the cardiac myosin‐binding protein C.
Qinghang Meng, Bidur Bhandary, Hanna Osinska, Jeanne James, Na Xu, Kritton Shay‐Winkler, James Gulick, Monte S. Willis, Cynthia Lander, Jeffrey Robbins   +9 more
doaj   +2 more sources

Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
The management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten. Unlike traditional pharmacotherapy, which primarily addresses symptoms, CMIs target the underlying mechanism of sarcomeric hypercontractility, offering significant reductions in left ...
Ferraresi B, Nenna A, Jawabra M, Corrado D, Faggiano A, Carugo S, Dominici C, Casali G, Chello M, Lusini M.   +9 more
europepmc   +2 more sources

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure
Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
doaj   +2 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +2 more sources